:: Volume 9, Issue 1 (Summer 2006) ::
EBNESINA 2006, 9(1): 40-44 Back to browse issues page
Anti hyperlipidemia drugs and flight
K Ghazizadeh *
Abstract:   (14423 Views)
Nowadays one of the most important reasons of death is Atherosclerosis. Drug therapy in hyperlipidemia prevents from Atherosclerosis side effects (such as cardiac attack, peripheral arterial diseases & strokes) and reduces mortality in patients with past history of hyperlipidemia and cardiovascular diseases. FAA (In civil part) permits aircrew to use some of these medications if there is not any side effects as Health Canadian Air Force Guidelines (In military part), pharmalogical treatment for hyperlipidemia should be initiated only after a reasonable trial of diet and life-style modification and if required treatment with an HMGCoA reductase inhibitor is recommended. In hypertrigliceridemia the use of a fibrate maybe indicated. Aircrew should be grounded for the first two weeks during the initiation of drug therapy for hyperlipidemia and require bimonthly monitoring of lipid & transaminase levels during the first six months of treatment and can use these drugs during flight if there are not any side effects.
Keywords: Atherosclerosis, Hyperlipidemia, Flight
Full-Text [PDF 243 kb]   (2813 Downloads)    
Type of Study: Original |
Received: 2012/03/8 | Accepted: 2014/06/3 | Published: 2014/06/3


XML   Persian Abstract   Print



Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 9, Issue 1 (Summer 2006) Back to browse issues page